On March 28, 2024 Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported two posters will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, demonstrating the potential of its SORT1+ Technology platform – including novel camptothecin-peptide conjugates and its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), as anticancer treatments (Press release, Theratechnologies, MAR 28, 2024, View Source [SID1234641579]). The AACR (Free AACR Whitepaper) meeting is taking place April 5-10 in San Diego, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These preclinical presentations reinforce existing data for sudocetaxel zendusortide to activate anti-PD-L1 immunotherapy tumor cell killing in SORT+1 cancers and provide the first evidence for novel camptothecin-peptide conjugates in the treatment of SORT+1 colorectal cancers.
"The studies we are presenting at the AACR (Free AACR Whitepaper) 2024 meeting highlight the significant advancements made on our SORT+1 Technology platform through careful assessment of investigational compounds, including sudocetaxel zendusortide, which is currently being evaluated in a Phase 1 trial in patients with advanced ovarian cancer," said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. "These data showcase the potential of our PDC candidates with different payloads as potential future treatment options for a broad range of cancer types."
Theratechnologies will present the following data at AACR (Free AACR Whitepaper) 2024:
Monday April 8, 2024: 9:00am-12:30pm Pacific Time (PT)
Title: Pre-clinical evidence for new camptothecin-peptide conjugates in the treatment of sortilin-positive colorectal cancers
Presenting Author: Sanjoy Kumar Das, Ph.D., Theratechnologies
Session Category: Experimental and Molecular Therapeutics
Session Title: New Technologies
Location: Poster Section 28
Poster Board Number: 28
Abstract Presentation Number: 2071
Monday April 8, 2024: 1:30pm- 5:00pm Pacific Time (PT)
Title: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing
Presenting Author: Michel Demeule, Ph.D., Theratechnologies
Session Category: Clinical Research Excluding Trials
Session Title: Combination Immunotherapies
Location: Poster Section 43
Poster Board Number: 3
Abstract Presentation Number: 3717
About Sudocetaxel Zendusortide (TH1902) and SORT1+ Technology
Sudocetaxel zendusortide is a first-of-its-kind sortilin receptor (SORT1)-targeting PDC, and the first compound to emerge from the Company’s broader licensed oncology platform. A new chemical entity, sudocetaxel zendusortide employs a cleavable linker to conjugate (attach) a proprietary peptide to docetaxel, a well-established cytotoxic chemotherapeutic agent used to treat many cancers. The FDA granted Fast Track designation to sudocetaxel zendusortide as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy. Sudocetaxel zendusortide is currently being evaluated in a Phase 1 clinical trial.
Theratechnologies has established the SORT1+ TechnologyTM platform as an engine for the development of PDCs that target SORT1, which is expressed in multiple tumor types. SORT1 is a "scavenger" receptor that plays a significant role in protein internalization, sorting, and trafficking. Expression of SORT1 is associated with aggressive disease, poor prognosis, and decreased survival. It is estimated that SORT1 is expressed in 40% to 90% of endometrial, ovarian, colorectal, triple-negative breast (TNBC), and pancreatic cancers, making this receptor an attractive target for anticancer drug development.